Yuliasih Yuliasih

Dr. Yuliasih Yuliasih

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Henry SutantoHenry Sutanto
Henry Sutanto
YYYuliasih Yuliasih
Yuliasih Yuliasih
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease that attacks various organ systems with a variety of clinical implications, ranging from mild skin and mucosal manifestations to severe central nervous system manifestations and death. Cases of SLE have been documented nearly two centuries ago when scholars used the terms ‘erythema centrifugum’ and ‘seborrhea congestiva’ to describe the discoid skin lesions and the butterfly or malar rash in SLE. Since then, knowledge about this disease has developed rapidly, especially knowledge related to the underlying pathogenesis of SLE. To date, it is known that immune system dysregulation, supported by genetic and environmental predisposition, can trigger the occurrence of SLE in a group of susceptible individuals. Various inflammatory mediators, cytokines and chemokines, as well as intra- and intercellular signaling pathways, are involved in the pathogenesis of SLE. In this review, we will discuss the molecular and cellular aspects of SLE pathogenesis, with a focus on how the immune system, genetics and the environment interact and trigger the various clinical manifestations of SLE.

8 November 2022 in International Journal of Inflammation
Verified
Journal Article
Open access
PDF file
YYYuliasih Yuliasih
Yuliasih Yuliasih
LRLita Diah Rahmawati
Lita Diah Rahmawati
NNNabilatun Nisa’
Nabilatun Nisa’
CPCahaya Prastayudha
Cahaya Prastayudha
Several key player factors, such as cytokine and complement, play an important role in the pathogenesis of systemic lupus erythematosus (SLE). The purpose of this study was to reveal the association between complement 3 (C3), complement 4 (C4), interleukin-6 (IL-6), and transforming growth factor-β (TGF-β) with SLE disease activity, renal damage, and hematological activity in patients with naïve SLE. The Laboratory of Clinical Pathology Dr. Soetomo General Hospital in Surabaya performed all laboratory examinations on thirty women with naïve SLE. The SLE diagnosis is based on ACR criteria (1998 revised criteria) from Dr. Soetomo General Hospital Surabaya, Indonesia, and the systemic lupus activity measurement (SLAM) score is used to assess the disease activity. The correlation was statistically tested using the Spearman and Pearson tests. The differences in cytokine and complement levels are between SLE severity groups using the two-way Anova and Kruskal–Wallis. The unpaired T-test and Mann–Whitney test were used to determine the differences between the relatively normal and the more severe groups of organ damage and hematological activity. All tests were two-tailed, analyzed with GraphPad Prism 9 for windows, and a value of less than 0.05 was considered statistically significant. This study found a significant decrease in C3 (20.2, 16.4–24.2 mg/dL) and C4 (7, 6–14.3 mg/dL) and an increase in IL-6 (35.60 ± 7.43 mg/dL) and TGF-β (311.1 ± 290.8 mg/dL) in the group of severe patients with SLAM scores >30. Although there is no significant relationship between SLAM and renal impairment or hematologic activity, patients with higher SLAM had a significant decrease in complement; this complement decrease was also significant in patients with higher leukocyte counts. An insignificant increase in cytokines was also observed in patients with higher SLAM. Patients with high serum creatinine levels had a significant increase in TGF-β, whereas those with a faster ESR had a significant increase in IL-6. In conjunction with complements evaluation, assessment of the cytokine profile may become a promising marker for reliable diagnosis and treatment of SLE in the future.

23 May 2023 in Autoimmune Diseases
Verified
Journal Article
Open access
PDF file
YYYuliasih Yuliasih
Yuliasih Yuliasih
APAghnia Permatasari
Aghnia Permatasari
LRLita Diah Rahmawati
Lita Diah Rahmawati
MWMohammad Imam Wahyudi
Mohammad Imam Wahyudi
NNNabilatun Nisa’
Nabilatun Nisa’
The role of dickkopf-related protein 1 (DKK-1) in radiographic development may become a robust marker for early spondyloarthritis (SpA) diagnosis. This study aimed at determining the serum DKK-1 profile in patients with SpA and investigating its relationship with SpA progression. Supported by analyzing the BMD data which aims to affirm the potential of DKK-1 as a biomarker for early diagnosis of SpA, this research may become the early study to produce a robust tool to diminish the fatal impacts in SpA. This cross-sectional study included patients with SpA using ASAS 2010 criteria from Dr. Soetomo General Hospital, Indonesia. Collected data included patients’ general characteristics, disease duration, disease activity using ASDAS-CRP and ASDAS-ESR, serum DKK-1 levels, and BMD. The patients were classified as early SpA if the disease duration was ≤5 years and established SpA if the disease duration was >5 years, while the low BMD was indicated by Z score ≤ −2.00. The correlation was tested using the Spearman or Pearson test. The differences in patients’ characteristics among early and established SpA and also between low and normal BMD were tested using the unpaired T-test or the Mann–Whitney test. The serum DKK-1 levels in early SpA (7365 ± 2067 pg/dL) were significantly higher than those in established SpA (5360 ± 1054 pg/dL). Serum DKK-1 levels were also associated with disease duration (r = −0.370, ) and BMD at the total hip (r = 0.467, ). The differences in all patients’ clinical parameters were not found between patients with low BMD at any site and patients with normal BMD unless in the BMI ( ). Our findings found DKK-1 as a potential diagnostic marker for early SpA. Early diagnosis may lead to rapid treatment to delay disease progression and prevent future impairment.

31 May 2023 in Journal of Psoriasis and Psoriatic Arthritis®
Verified
Journal Article
Closed access
YYYuliasih Yuliasih
Yuliasih Yuliasih
MHMartino Handoyo
Martino Handoyo
LRLita Diah Rahmawati
Lita Diah Rahmawati
SWSony Wibisono
Sony Wibisono
NNNabilatun Nisa
Nabilatun Nisa
Objectives: Most psoriatic arthritis (PsA) research and studies focus solely on the skin and joint manifestations, but there is also an increased risk of metabolic disorders, including insulin resistance (IR). This study aims to discover the relationship between IR and disease activity (DA) in PsA and its phenotype. Materials and methods: Patients with PsA classified using the CASPAR criteria with the disease activity was measured using the DAPSA score, and IR was identified as an elevated HOMA-IR of >2.5. The disease phenotype was determined with Moll and Wright’s classification of the PsA subtype. The Pearson correlation test examined the relationship between DA and IR. The descriptive analysis was conducted to determine the relationship between the DAPSA score and HOMA-IR value in each PsA phenotype. All tests were two-tailed, analysed with GraphPad Prism 9, and a P-value of less than .05 was considered statistically significant. Results: From thirty-one patients, there was a strong and positive relationship between DA and IR (r = .768, P = .000). We also observed variations in DAPSA score and HOMA-IR value across different phenotypes, with symmetrical polyarthritis exhibiting the highest DAPSA score (21.55 ± 3.50) and HOMA-IR value (2.913 ± .5392) despite asymmetrical oligoarthritis that being the most frequent phenotype. Conclusion: Our study revealed a significant association between disease activity and insulin resistance in PsA patients, with the symmetrical polyarthritis phenotype demonstrating the highest levels of DAPSA score and IR value. This finding allowed rheumatologists to behold this manifestation and could improve PsA patients' long-term outlook.

8 December 2025 in Egyptian Rheumatology and Rehabilitation
Verified
Journal Article
Open access
PDF file
YYYuliasih Yuliasih
Yuliasih Yuliasih
BRBetty Rachma
Betty Rachma
AAAwalia Awalia
Awalia Awalia
LRLita Diah Rahmawati
Lita Diah Rahmawati
CNCahyo Wibisono Nugroho
Cahyo Wibisono Nugroho
Henry SutantoHenry Sutanto
Henry Sutanto
Introduction: Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. Methodology: This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Discussion: Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Future directions: Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Conclusion: Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.

4 December 2025 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
YYYuliasih Yuliasih
Yuliasih Yuliasih
BRBetty Rachma
Betty Rachma
Henry SutantoHenry Sutanto
Henry Sutanto